Cancer treatment delays among cancer patients living with HIV during the COVID-19 pandemic in the United States
- PMID: 37712718
- PMCID: PMC10557907
- DOI: 10.1002/cam4.6489
Cancer treatment delays among cancer patients living with HIV during the COVID-19 pandemic in the United States
Abstract
Background: The COVID-19 pandemic led to care disruptions across the cancer continuum. It is unknown if immunosuppressed patients with cancer, who may be at higher risk for complications of SARS-CoV-2 infection, are disproportionately impacted. Thus, we aimed to compare delays in cancer treatment initiation between people living with HIV (PLWH) and cancer, the general cancer population (GCP), and patients with cancer and a history of solid organ transplant (SOT). Comparisons were made across the period 2 years preceding the pandemic versus the first year of the pandemic.
Methods: We used data from a real-world electronic health record-derived de-identified database (2018-2021) comprised of US patients with cancer from 800 sites of care across the country. We included patients with 19 different cancer types. We calculated time to cancer treatment initiation (TTI) as the difference between the date of cancer diagnosis and the earliest date that cancer treatment was recorded.
Results: The sample included 181 PLWH, 65,073 GCP patients, and 195 patients with a SOT. Difference-in-difference regression models adjusted for age, sex, and presence of metastatic disease at cancer diagnosis revealed a significant increase in delayed TTI among PLWH compared to the GCP during COVID-19 versus prior to COVID-19, with delays increasing by approximately 1 month during the pandemic (DID: 32.6 days [8.9-56.3]; p = 0.007). The increase in TTI for PLWH was observed across treatment modalities, including surgery (DID: 55.1 [28.8-81.3], p < 0.001) and systemic therapy (DID: 30.4 [4.6-56.3], p = 0.021).
Conclusions/relevance: PLWH experienced significant delays in cancer treatment initiation after diagnosis during the first year of COVID-19, delays that may negatively impact cancer outcomes. These data warrant patient and provider attention as the pandemic continues to impact the US healthcare system.
Keywords: COVID-19; HIV and cancer; cancer.
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States.J Natl Cancer Inst. 2022 Apr 11;114(4):571-578. doi: 10.1093/jnci/djab225. J Natl Cancer Inst. 2022. PMID: 34893865 Free PMC article.
-
Impact of the COVID-19 pandemic on treatment patterns for US patients with metastatic solid cancer.medRxiv [Preprint]. 2021 Sep 23:2021.09.22.21263964. doi: 10.1101/2021.09.22.21263964. medRxiv. 2021. Update in: J Natl Cancer Inst. 2022 Apr 11;114(4):571-578. doi: 10.1093/jnci/djab225. PMID: 34611665 Free PMC article. Updated. Preprint.
-
A Systematic Review: Impact of SARS-CoV-2 Infection on Morbidity, Mortality, and Viral Suppression in Patients Living With HIV.SN Compr Clin Med. 2023;5(1):144. doi: 10.1007/s42399-023-01480-6. Epub 2023 May 15. SN Compr Clin Med. 2023. PMID: 37214621 Free PMC article. Review.
-
Systematic Review and Meta-Analyses of The Interaction Between HIV Infection And COVID-19: Two Years' Evidence Summary.Front Immunol. 2022 May 10;13:864838. doi: 10.3389/fimmu.2022.864838. eCollection 2022. Front Immunol. 2022. PMID: 35619709 Free PMC article.
-
COVID-19 Outcomes and Risk Factors Among People Living with HIV.Curr HIV/AIDS Rep. 2022 Oct;19(5):425-432. doi: 10.1007/s11904-022-00618-w. Epub 2022 Aug 5. Curr HIV/AIDS Rep. 2022. PMID: 35930187 Free PMC article. Review.
Cited by
-
Cancer Treatment Disparities in People With HIV in the United States, 2001-2019.J Clin Oncol. 2024 May 20;42(15):1810-1820. doi: 10.1200/JCO.23.02366. Epub 2024 Mar 21. J Clin Oncol. 2024. PMID: 38513161 Free PMC article.
References
-
- Administration, U. S. F. D . FDA drug shortages . Retrieved March 21 from https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
LinkOut - more resources
Full Text Sources
Miscellaneous